Table 1.
Clinical characteristics of patients receiving exogenous digestive enzyme replacement
| Number of patients | 33 (100%) |
| Female/male | 21 (64 %) |
| Birth weight (g) | 855 (375–1230) |
| Small for gestational age (< 10th percentile) | 7 (21 %) |
| Gestational age (weeks) | 26 0/7 (23 0/7–31 0/7) |
| CRIB (clinical risk index for babies) | 6 (1–13) |
| Supplemental oxygen requirement at 36-week postmenstrual age | 4 (12 %) |
| Patent ductus arteriosus treated with ibuprofen | 7 (21 %) |
| Retinopathy of prematurity treated with bevacizumab | 2 (6 %) |
| Intraventricular hemorrhage | 4 (12%) |
| Antibiotics (any time t0 – 14 d until t0 +14 d) | 12 (36 %) |
| Fecal pancreatic elastase-1 (μg/g) | 88 (31–187) |
| Duration of exogenous digestive enzyme replacement (days) | 27 (5–60) |
Data are presented as numbers (percentage) of subjects or median (range)